ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,101.24
-0.29%
US Tech 100
20,438.00
-3.53%
다우존스 지수
44,424.25
-0.32%
Bitcoin
99,051.86
-5.37%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. NewAmsterdam Pharma Company NV (NAMSW)

  7. NewAmsterdam Pharma Company NV (NAMSW) 뉴스

NAMSW

NewAmsterdam Pharma Comp... (NAMSW)

NewAmsterdam Pharma Company NV
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:NAMSW
일자시간출처헤드라인심볼기업
2025/01/1106:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/1022:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/1022:00GlobeNewswire Inc.NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic PrioritiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/1005:38GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0907:58Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0807:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0807:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0807:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0806:29Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0707:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0707:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2025/01/0707:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1407:16GlobeNewswire Inc.NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1322:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1320:33Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1211:37GlobeNewswire Inc.NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1209:57Edgar (US Regulatory)Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1106:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1106:34GlobeNewswire Inc.NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1106:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1021:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/1021:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial HypercholesterolemiaNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/12/0706:01GlobeNewswire Inc.NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/2021:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/2021:00GlobeNewswire Inc.NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFHNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/1906:11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/1905:20GlobeNewswire Inc.NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/1406:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/0622:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NAMSWNewAmsterdam Pharma Company NV
2024/11/0622:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NAMSWNewAmsterdam Pharma Company NV
 검색 관련기사 보기:NASDAQ:NAMSW

최근 히스토리

FX
USDJPY
US Dollar vs Yen
COIN
BTCUSD
Bitcoin
NASDAQ
NVDA
NVIDIA
CCOM
US500
US 500
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
SILVER
SILVER
CCOM
US30
US 30
AMEX
XLV
Health Care Select Sector
NASDAQ
TSLA
Tesla
USOTC
BASFY
BASF (QX)
FX
USDGBP
US Dollar vs Sterling
NYSE
DIS
Walt Disney
USOTC
BNPQY
BNP Paribas (QX)
NYSE
KO
Coca Cola
PM
XAUUSD
Gold vs US Dollar
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유